Xaliproden lessens oxaliplatin-mediated neuropathy.
Susman
Ed
E
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy; D006801:Humans; D009281:Naphthalenes / Q000494:pharmacology*; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D011725:Pyridines / Q000494:pharmacology*
D000970:Antineoplastic Agents; D009281:Naphthalenes; D009944:Organoplatinum Compounds; D011725:Pyridines; D000077150:Oxaliplatin; C462299:xaliproden